

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Hong Kong prospectus dated December 16, 2022 (the “Prospectus”) of Cryofocus Medtech (Shanghai) Co., Ltd. (the “Company”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”) or any state securities laws of the United States.*

*The securities may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*Potential investors of the Offer Shares should note that the Joint Representatives (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, December 30, 2022).*

*No stabilizing manager will be appointed and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.*



**Cryofocus Medtech (Shanghai) Co., Ltd.**

**康豐生物科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

## GLOBAL OFFERING

<b>Number of Offer Shares under the Global Offering</b>	<b>: 11,110,000 H Shares</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 1,111,000 H Shares (subject to reallocation)</b>
<b>Number of International Offer Shares</b>	<b>: 9,999,000 H Shares (subject to reallocation)</b>
<b>Offer Price</b>	<b>: HK\$18.90 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)</b>
<b>Nominal value</b>	<b>: RMB1.00 per H Share</b>
<b>Stock Code</b>	<b>: 6922</b>

*Joint Sponsors, Joint Representatives, Joint Global Coordinators,  
Joint Bookrunners and Joint Lead Managers*



*Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*



*Joint Bookrunners and Joint Lead Managers*



*Joint Lead Manager*



**IMPORTANT NOTICE TO INVESTORS:  
FULLY ELECTRONIC APPLICATION PROCESS**

**We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.**

**The Prospectus is available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at [www.cryofocus.com](http://www.cryofocus.com). If you require a printed copy of the Prospectus, you may download and print from the website addresses above.**

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk);
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
  - (i) instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
  - (ii) (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

**If you are an intermediary, broker or agent, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.**

Please refer to “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or the **CCASS EIPO** service must be for a minimum of 200 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>
	<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>
200	3,818.10	3,000	57,271.46	25,000	477,262.10	100,000	1,909,048.37
400	7,636.19	4,000	76,361.93	30,000	572,714.51	150,000	2,863,572.55
600	11,454.30	5,000	95,452.42	35,000	668,166.93	200,000	3,818,096.73
800	15,272.39	6,000	114,542.90	40,000	763,619.34	250,000	4,772,620.92
1,000	19,090.49	7,000	133,633.39	45,000	859,071.77	300,000	5,727,145.10
1,200	22,908.57	8,000	152,723.87	50,000	954,524.19	350,000	6,681,669.28
1,400	26,726.67	9,000	171,814.36	60,000	1,145,429.02	400,000	7,636,193.46
1,600	30,544.78	10,000	190,904.83	70,000	1,336,333.85	450,000	8,590,717.65
1,800	34,362.87	15,000	286,357.26	80,000	1,527,238.69	500,000	9,545,241.83
2,000	38,180.97	20,000	381,809.68	90,000	1,718,143.53	555,400 <sup>(1)</sup>	10,602,854.62

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

## THE LISTING APPLICATION

We have applied to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering and the H Shares to be converted from a total of 102,986,598 Unlisted Shares.

## **STRUCTURE OF THE GLOBAL OFFERING**

The Global Offering comprises:

- the Hong Kong Public Offering of initially 1,111,000 H Shares (subject to reallocation) in Hong Kong, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 9,999,000 H Shares (subject to reallocation), representing approximately 90% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, the Joint Representatives may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be available under the Hong Kong Public Offering following such reallocation shall be not more than double the initial allocation to the Hong Kong Public Offering (i.e. 2,222,000 Offer Shares, representing approximately 20% of the total number of Offer Shares initially available under the Global Offering).

## PRICING

The Offer Price will be HK\$18.90 per Offer Share. Applicants for the Hong Kong Offer Shares are required to pay, on application, the Offer Price of HK\$18.90 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%.

## EXPECTED TIMETABLE

Hong Kong Public Offering commences..... 9:00 a.m. on  
Friday, December 16, 2022

Latest time to complete electronic applications  
under **White Form eIPO** service through the  
designated website at [www.eipo.com.hk](http://www.eipo.com.hk) ..... 11:30 a.m. on  
Wednesday, December 21, 2022

Application lists of the Hong Kong Public Offering open..... 11:45 a.m. on  
Wednesday, December 21, 2022

Latest time to (a) complete payment of **White Form eIPO** applications  
by effecting internet banking transfers(s) or PPS payment transfer(s)  
and (b) give **electronic application instructions** to HKSCC ..... 12:00 noon on  
Wednesday, December 21, 2022

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists of the Hong Kong Public Offering close ..... 12:00 noon on  
Wednesday, December 21, 2022

Announcement of the results of applications  
in the Hong Kong Public Offering, the level of indications of  
interest in the International Offering, and the basis of allocation  
of the Hong Kong Offer Shares under the Hong Kong Public  
offering to be published on the website on the website of  
the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the website  
of the Company at [www.cryofocus.com](http://www.cryofocus.com) ..... Thursday, December 29, 2022

Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- (1). A full announcement of the Hong Kong Public Offering to be published on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the website of the Company at [www.cryofocus.com](http://www.cryofocus.com) respectively ..... Thursday, December 29, 2022
- (2). Results of allocations in the Hong Kong Public Offering will be available at [www.iporeresults.com.hk](http://www.iporeresults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a "search by ID" function from ..... 8:00 a.m. on Thursday, December 29, 2022 to 12:00 midnight on Wednesday, January 4, 2023
- (3). Allocation results telephone enquiry by calling +852 2862 8555 ..... between 9:00 a.m. and 6 p.m. on Thursday, December 29, 2022  
Friday, December 30, 2022  
Tuesday, January 3, 2023 and  
Wednesday, January 4, 2023

Dispatch/collection of refund cheques and **White Form** e-Refund payment instructions in respect of wholly or partially successful (if applicable) and wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering on or before ..... Thursday, December 29, 2022

Dispatch/collection of H Share certificates or deposit of the H Share certificates into CCASS in respect of wholly or partially successful applications pursuant to the Hong Kong Public Offering on or before ..... Thursday, December 29, 2022

Dealings in the H Shares on the Stock Exchange expected to commence at 9: 00 a.m. on ..... Friday, December 30, 2022

*Note:* Unless otherwise stated, all times and dates refer to Hong Kong local times and dates.

## SETTLEMENT

Subject to the granting of the approval for listing of, and permission to deal in, the H Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or any other date as determined by HKSCC. Settlement of transactions between Exchange Participants (as defined in the Hong Kong Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. Investors should seek the advice of their stockbrokers or other professional advisers for the details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made for the H Shares to be admitted into CCASS.

## ELECTRONIC APPLICATION CHANNELS

### Applying Through the White Form eIPO Service

You may submit your application through the White Form eIPO service for the Offer Shares to be allotted and registered in your own names through the designated website at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last day for applications) from 9:00 a.m. on Friday, December 16, 2022 until 11:30 a.m. on Wednesday, December 21, 2022 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Wednesday, December 21, 2022, the last day for applications, or such later time as described in “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

### Applying Through the CCASS EIPO Service<sup>(1)</sup>

CCASS Clearing/Custodian Participants can input electronic application instructions at the following times on the following dates:

Friday, December 16, 2022	–	9:00 a.m. – 8:30 p.m.
Monday, December 19, 2022	–	8:00 a.m. – 8:30 p.m.
Tuesday, December 20, 2022	–	8:00 a.m. – 8:30 p.m.
Wednesday, December 21, 2022	–	8:00 a.m. – 12:00 noon

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Friday, December 16, 2022 until 12:00 noon on Wednesday, December 21, 2022 (24 hours daily, except on Wednesday, December 21, 2022, the last day for applications).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Wednesday, December 21, 2022, the last day for applications or such later time as described in “How to Apply for the Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

*Note:*

- (1) The times in this subsection are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.



If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

The application monies (including the brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, December 29, 2022.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

**Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the GREEN Application Form and on the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for the White Form eIPO service.**

## **PUBLICATION OF RESULTS**

The Company expects to announce the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Thursday, December 29, 2022 on the Company’s website at [www.cryofocus.com](http://www.cryofocus.com), and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for the Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with “Structure of the Global Offering – The Hong Kong Public Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared.

The Company will not issue temporary document of title in respect of the Offer Shares. The Company will not issue receipt for sums paid on application. H Share certificates will only become valid at 8:00 a.m. (Hong Kong time) on Friday, December 30, 2022, provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of the H Share certificates or prior to the H Share certificates becoming valid do so entirely at their own risk.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, December 30, 2022 (Hong Kong time), dealings in the Company's H Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, December 30, 2022 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each.

The stock code of the Company's H Shares will be 6922.

By order of the Board  
**Cryofocus Medtech (Shanghai) Co., Ltd.**  
**Mr. LI Kejian**  
*Chairman of the Board*

Hong Kong, December 16, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. LI Kejian and Mr. ZHU Jun as executive Directors, Mr. LV Shiwen, Mr. SUN Xiaolu and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.*